that the overall survival rate and non-relapse mortality rate after a second allogeneic HSCT (allo-HSCT) were approximately 30Á9% and 35Á1%, respectively, among patients with relapsed haematological malignancies (some patients received DLI before the second allo-HSCT) . Donor lymphoblastic infusion is another important treatment strategy for B-ALL relapse after haplo-HSCT. In another study, we found that the complete remission (CR) rate of DLI was approximately 64Á0% among patients with relapsed acute leukaemia after haplo-HSCT, with a 1-year disease-free survival rate of 36Á0% (Yan et al, 2013) . However, approximately one-third of patients are non-responsive to DLI, and new second-line interventions are urgently needed for these patients. Several promising adoptive therapies have been developed to address this need, including chimeric antigen receptor (CAR)-engineered T cells (Reis et al, 2016) .
CD19-directed CAR T cells (CART19s) can eliminate leukaemic cells and potentially cure leukaemia, especially in patients with relapsed ALL (Grupp et al, 2013) . Generally, CAR T cells can be collected from either the allo-HSCT recipient or donor. However, because relapsed patients have a high leukaemia burden, it may be difficult to obtain sufficient T cells from them, especially after chemotherapy. Donor CAR T cells exert potent graft-versus-leukaemia (GVL) activity in the absence of damaging graft-versus-host disease (GVHD) activity (Ghosh et al, 2017) and without the influence of the cytotoxic activity of CAR T cells (Davies et al, 2010) . Although several studies have evaluated human leucocyte antigen (HLA)-matched sibling donor or unrelated donor allogeneic blood or marrow transplantation (Kochenderfer et al, 2013; Dai et al, 2015; , the few reports of donor-derived CAR T cells infusion after HSCT, especially after haplo-HSCT, are insufficient despite the significant increase in haplo-HSCT use over the past several years (Montoro et al, 2016) . More importantly, nonresponders to DLI have a very poor prognosis, and no effective approaches are available to these patients. Therefore, we report here the preliminary clinical results of donor-derived CAR T-cell treatment in patients with relapsed B cell malignancies who were non-responsive to DLI after haplo-HSCT.
Methods

Patients
Patients who had received a CAR T-cell infusion between January 2015 and January 2017 at the Peking University Institute of Haematology were included in the present study if they met the following criteria: (i) diagnosed with B-ALL; (ii) had suffered a morphological relapse after haplo-HSCT; (iii) were non-responsive to one or more DLIs (no response was defined as ≥5% lymphoblasts in bone marrow aspirate 25-30 days after DLI); and (iv) had CD19 expression on leukaemic cells, confirmed by flow cytometry.
This study protocol was approved by the Peking University People's Hospital review board. Patients provided informed consent in compliance with the Declaration of Helsinki.
Haplo-HSCT procedure
The transplant procedure, including the conditioning regimen, GVHD prophylaxis, stem cell collection and supportive care, was described in our previous report (Huang et al, 2006) . The following drugs were administered during the conditioning regimens: cytosine arabinoside (4 g/m 2 /day for 2 days), busulfan (3Á2 mg/kg/day for 3 days), cyclophosphamide (1Á8 g/m 2 /day for 2 days), simustine (250 mg/m 2 for 1 day) and anti-human thymocyte immunoglobulin (Thymoglobulin, Genzyme, Boston, MA, USA; 2Á5 mg/kg/day for 4 days). All patients received granulocyte colony-stimulating factor (G-CSF)-mobilized bone marrow cells plus peripheral blood stem cells. All transplant recipients received ciclosporin A (CsA), mycophenolate mofetil, and short-term methotrexate for prophylaxis against acute post-transplantation GVHD.
DLI procedure
In the present study, DLI consisted of an infusion of G-CSFmobilized peripheral blood stem cells after chemotherapy and post-infusion administration of immunosuppressive agents to prevent GVHD (Yan et al, 2014) . The median dose of mononucleated cells was 1910 8 /kg. After DLI, all patients received immunosuppressive agents, such as CsA, to prevent GVHD for 4-6 weeks at the discretion of the attending physician (usually depending on the patient's GVHD status after DLI). The initial dose of CsA was 2Á5 mg/kg/day; the dose was then adjusted to maintain a plasma concentration of 150-250 ng/ml. No response to DLI was defined as no morphological remission at 1 month after DLI.
Cell production
The CAR T cells infused into patients after haplo-HSCT were derived from the patients' transplant donors. Peripheral blood mononuclear cells were obtained from donors via leukapheresis or peripheral blood. The duration of CAR Tcell production was 5-15 days. Prior to CART19s infusion, CART19s for each patient were subjected to fluorescenceactivated cell sorting analysis of transduction efficiency and in vitro cytotoxicity assays. Additionally, CART19 cultures were evaluated for possible fungal, bacterial, mycoplasma, chlamydiaand endotoxin contamination. The other details of cell production are described in Appendix S1 and Appendix S2.
CAR T-cell infusion protocol
Patients were given a conditioning treatment for lymphodepletion. cyclophosphamide-based conditioning treatment according to the tumour burden and at the discretion of the attending physician (details are described in Tables I and  II) . CART19s were transfused directly to patients without premedication, and the dosages and characteristics of the infused cells are shown in Table III . Patients received a second CAR T cell infusion dose when the following criteria were fulfilled:
1 Evaluation revealed that the patients were non-responsive to the first infusion. 2 Positive minimal residual disease (MRD) or morphological relapse was observed.
Toxicity grading and GVHD
Toxicity was graded using the common criteria for cytokine release syndrome (CRS) after CAR T-cell infusion (Lee et al, 2014; . The possibility of infection was considered in all patients presenting with CRS symptoms after obtaining appropriate cultures and initiating empiric antibiotic treatment. GVHD was diagnosed as acute or chronic according to the clinical features of the affected organs, rather than the onset time after CAR T-cell infusion. Acute GVHD was graded according to previously published criteria (Huff et al, 2006) . Primary therapy consisting of methylprednisolone or a dexamethasone equivalent was administered when GVHD could not be ruled out. Methylprednisolone was administered intravenously at a dose of 1-2 mg/kg/day. Ciclosporin A was administered and then adjusted to maintain a blood concentration >50 ng/ml in some patients when GVHD was not controlled.
Response evaluation
A bone marrow examination was performed on Day 15 and/ or Day 30 after CAR T-cell infusion to assess the response. Subsequently, a bone marrow examination was performed every 1-3 months. A bone marrow smear and MRD detection by flow cytometry, fusion gene detection by quantitative real-time polymerase chain reaction (qPCR), and measurement of Wilms' tumour 1 (WT1) gene expression levels were performed for all patients.
1 Morphological B-ALL remission was defined as ≤5% lymphoblasts in a bone marrow aspirate. 2 MRD-negative CR was defined as a morphological remission and negative results on all MRD tests, including flow cytometry, WT1 expression levels, and fusion gene detection by qPCR (in patients with detectable fusion genes). All patients underwent bone marrow examination on Day 15 and/or Day 30 after CAR T-cell infusion, or sooner if clinically indicated. CAR, chimeric antigen receptor; CMV, cytomegalovirus; CR, complete remission; CsA, ciclosporin A; CTX, cyclophosphamide; Dex, dexamethasone; Flu, fludarabine; GVHD, graft-versus-host disease; Mit, mitoxantrone; MRD, minimal residual disease; MTX, methotrexate; TMA, thrombotic microangiopathies; VDS, vindesine.
Statistical analysis
The patients' characteristics were evaluated using descriptive statistics. Positivity rates were compared using Fisher's exact test, and qualitative variables were assessed using Student's ttest. All analyses were performed using SPSS software version 16 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Six patients (five females, one male; age range: 8-44 years) with relapsed B-ALL after haplo-HSCT were enrolled in this study. All patients experienced morphological relapse and were non-responsive to at least one course of DLI (Table IV) . Two patients each received one infusion and four patients each received two infusions (total infusions: 10), and the median CAR T cell infusion dose was 1Á7 9 10 8 cells/kg (range: 0Á38-4Á1 9 10 8 cells/kg). All patients were observed until April 2017.
Remission rate and clinical outcomes (Tables I and II) Four of six (66Á67%) patients achieved a MRD-negative CR after the first infusion and remained healthy for a median of 5Á5 months (range 2-7 months) after CAR T-cell infusion; Patients 1, 2, and 3 experienced a morphological relapse, and Patient 4 developed recurrent MRD. Patients 1, 3, and 4 
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received a second infusion but failed to achieve remission. Patient 5 developed thrombotic microangiopathies (TMAs) and was subsequently discharged after discontinuing treatment, with no further evaluation. Patient 6 was non-responsive to the first infusion but responded to a second infusion of CAR T cells prepared in a different manner after 32 days (peripheral blood response evaluated using flow cytometry). Unfortunately, she died 2 weeks later of an intracranial haemorrhage accompanied by septicaemia caused by a Gram-negative bacillus infection. In summary, five of six patients (83Á33%) achieved MRD-negative CR after CAR T-cell infusion. All details are summarized in Tables I and II .
Graft-versus-host disease
Two patients developed grade 2 aGVHD (skin and intestinal tract, one; skin and liver, one) during the responsive course of CAR T infusion. In both patients, GVHD was controlled by glucocorticoid therapy. Patient 5 developed Grade 3 aGVHD (skin, intestinal tract and liver) on the Day 9 after infusion and was treated with 2 mg/kg methylprednisolone combined with CsA and anti-CD25 monoclonal antibody on the Day 19 after infusion. Anti-GVHD therapy partly ameliorated rash and diarrhoea but did not yield a marked improvement in the total bilirubin level. The patient was diagnosed with TMA and auto-discharged.
Cytokine release syndrome
The toxicities observed after CAR T-cell infusion, including fever, hypotension, hypoxaemia and elevated alanine transaminase (ALT), were classified as CRS after ruling out other causes. CRS was scored according to a revised grading system (Lee et al, 2014) . The toxicities that occurred in each patient are listed in Table III . Five patients developed a total of eight CRS events; five events occurred after the first infusion (grade 1, two events; grade 2, one event; grade 3, two events). Three patients required medication interventions (etanercept, one patient; tocilizumab, two patients). Patient 1 developed a fever after the infusion, which abated after etanercept therapy. Patient 5 developed a rash, hypoxemia and an elevated ALTlevel (817 U/L) on the Day 6 after infusion, and received two doses of tocilizumab on the Days 8 and 9 after infusion. Although the rash, hypoxemia, and elevated ALT improved after tocilizumab administration, she was diagnosed with GVHD and TMA because of diarrhoea and lateronset jaundice. Patient 6 developed a rash on the Day 3 after the first infusion and experienced spontaneous remission. She then developed fever, hypoxemia, an elevated ALT level, hypoxia, dysfunctional blood coagulation and a rash on the Day 2 after the second infusion. These symptoms were controlled after two doses of tocilizumab.
Peripheral blood CAR T cells
During four infusion courses, CAR-T cells in the peripheral blood were measured by qPCR on Days 7, 14 and 21 after infusion. The number of CAR T cells in the peripheral blood peaked on the Day 14 and decreased by the Day 21 after infusion (Table III) .
Discussion
Relapse is the major cause of treatment failure after haplo-HSCT, and chemotherapy followed by DLI comprises an important treatment intervention for relapsed ALL in these cases. However, only a fraction of patients respond to DLI, and these patients have an increased risk of GVHD (Yan et al, 2014) . Furthermore, non-DLI-responders with relapsed B-ALL after haplo-HSCT have a very poor prognosis and limited treatment options. A previous report by Zuo et al (2016) describes the case of an 11-year-old girl with ETV6-RUNX1 (TEL-AML1) fusion gene-positive B-ALL who experienced a bone marrow relapse after haplo-HSCT. She received an infusion of donor-derived CART19s and maintained a MRD-negative remission for 10 months. However, to our knowledge, the present study comprises the largest investigation of donor-derived CART19 infusion in patients who relapsed after haplo-HSCT. Previous studies reported CR rates of roughly 30-64% among patients treated with chemotherapy followed by DLI for a haematological relapse after haplo-HSCT (Yan et al, 2013; Zeidan et al, 2014; Ghiso et al, 2015) . In the present study, five of six non-DLI-responders (83Á33%) with morphological relapses achieved a MRD-negative remission after receiving an infusion of CAR T cells; in other words, the outcome was superior to previous outcomes of DLI. We note that both DLI and a donor-derived CAR T-cell infusion after allo-HSCT from a HLA-matched sibling or unrelated donor can enhance the GVL effect, which is caused by the targeting of allogeneic antigens by donor lymphocytes (Huff et al, 2006; Magnani et al, 2015) . However, patients in the present study responded to an infusion of CART19s rather than DLI, suggesting that the mechanism underlying haploidentical donor-derived CAR T cell therapy may be distinct from that of DLI.
The outcomes in the present cases were also better than those reported previously in studies in which infusions of donor-derived CAR T cells induced remission in relapsed B-ALL patients after HLA-matched sibling or unrelated donor allo-HSCT. used donor-derived CAR19 cells to treat 20 patients with progressive disease after HLAmatched sibling or unrelated donor HSCT. In that study, eight patients (40%) achieved a morphological CR, including six complete and two partial remissions. Cruz and Bollard (2015) treated eight patients (four with chronic lymphocytic leukaemia and four with ALL) who had experienced or were at a high risk of disease relapse after allo-HSCT and observed objective evidence of antitumour activity in two of six patients. CAR T cells may have a stronger effect in cases of haplo-HSCT, compared with non-haplo-HSCT, and we have observed that haplo-SCT can achieve a stronger GVL effect than immunosuppressive drugs for high-risk patients with acute leukaemia . However, the biological mechanism requires further exploration.
In our study, all four MRD-negative patients relapsed after remissions of 2-7 months. This suggests that the effects of haploidentical CAR T cells do not persist over the long term and is consistent with the reduced numbers of CAR T cells in peripheral blood. Accordingly, these patients will require subsequent therapy. Furthermore, three of the patients did not respond to a second infusion, indicating that multiple infusions of CAR T cells may not be effective.
In the present study, the safety of donor-derived CARmodified T-cell infusions for recipients of haplo-HSCT was mainly evaluated with respect to CRS and aGVHD. Five of six patients (83Á33%) with haplo-HSCT developed a total of eight episodes of CRS, which was effectively managed by tocilizumab in two (33Á33%) patients. No patient died directly of CRS. Previously, the most severe reported manifestation of CRS was neurotoxicity, particularly cerebral oedema ; however, no cases of CRS-related cerebral oedema occurred in the present study. Three patients (50%) exhibited dysfunctional coagulation, characterized by decreased fibrinogen and elevated Ddimer levels and a prolonged activated partial thromboplastin time. Although this incidence of coagulation dysfunction among patients who underwent haplo-HSCT was higher than that reported among patients who underwent non-haplo-HSCT, this condition was effectively managed with drug treatment .
Regarding aGVHD, another complication of concern, three (50%) patients developed grade 2 or grade 3 aGVHD. In a study of 40 patients who received DLI after haplo-HSCT, Zeidan et al (2014) found that 10 (25%) developed aGVHD, which was grades 3-4 in six (15%) of them. Our own previous work demonstrated cumulative incidences of DLI-associated aGVHD of 53Á2% for grade II and 28Á4% for grade III among 124 cases receiving modified DLI after haploidentical T-cell-replete HSCT (Yan et al, 2012) . Therefore, the incidence of aGVHD in the present study was not higher or more severe than that in patients who received DLI after haplo-HSCT. Ghosh et al (2017) proposed that donor CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity, and observed no cases of new-onset aGVHD after CAR T cell infusion among patients who had undergone HLAmatched sibling or unrelated donor allo-HSCT. However, aGVHD occurred almost simultaneously with CRS in the present study, and the conditions were difficult to distinguish. Briefly, aGVHD induced by donor-derived CAR T cells after haplo-HSCT is not as detrimental as previously thought, consistent with our previous results (Chen et al,2016) .
Based on these observations, we propose that donorderived CAR T cell infusion is an effective and safe intervention for treating relapsed B cell malignancies after haplo-HSCT; however, the underlying mechanism is not clear. Larger-scale clinical trials are required to confirm the findings of this study and to determine the underlying mechanism. 
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